Taylor & Francis Group
Browse
ieds_a_1713090_sm0872.docx (45.42 kB)

Cefoperazone-sulbactam and risk of coagulation disorders or bleeding: a retrospective cohort study

Download (45.42 kB)
journal contribution
posted on 2020-01-27, 15:52 authored by Wen Wang, Yanmei Liu, Chuan Yu, Jing Tan, Weiyi Xiong, Duo Dong, Sheyu Li, Rui Zhang, Jijie Li, Yu Wu, Zhiyong Zong, Na Su, Kang Zou, Guizhi Wu, Xin Sun

Objectives: Limited evidence has suggested that cefoperazone-sulbactam causes coagulation disorders and bleeding.

Methods: The authors conducted a retrospective study to compare patients receiving cefoperazone-sulbactam versus those treated with cefoperazone-tazobactam or ceftazidime. Propensity-score matching was used to explore whether treatment with cefoperazone-sulbactam increased the risk of prothrombin time (PT) prolongation, coagulation disorders, and bleeding, or decreased platelets (PLT).

Results: The cohort included 23,242 patients. Among patients receiving cefoperazone-sulbactam, the risk of PT prolongation, coagulation disorders, decreased PLT, and bleeding was 5.3%, 9.2%, 15.7%, and 4.2%, respectively. Propensity-score matching analyses suggested that cefoperazone-sulbactam increased the risk of PT prolongation (aOR 2.26, 95% CI 1.61–3.18), coagulation disorders (aOR 1.81, 95% CI 1.43–2.30), and decreased PLT (aOR 1.46, 95% CI 1.25–1.72), but not increase bleeding (aOR 1.05, 95% CI 0.79–1.40) compared with ceftazidime. Patients receiving cefoperazone-sulbactam had higher risk of PT prolongation (aOR 1.53, 95% CI 1.11–2.10), coagulation disorders (aOR 1.53, 95% CI 1.21–1.95), but not decreased PLT (aOR 0.93, 95% CI 0.81–1.07) or bleeding (aOR 1.11, 95% CI 0.87–1.42), compared with those receiving cefoperazone-tazobactam.

Conclusion: Cefoperazone-sulbactam may be associated with a higher risk of PT prolongation and coagulation disorders compared with cefoperazone-tazobactam and ceftazidime.

Funding

This study was supported by the National Center for ADR monitoring of China (Grant No. HX-H1612129), The National Natural Science Foundation of China (Grant No. 71573183), and ‘Thousand Youth Talents Plan’ of China (Grant No. D1024002) and Sichuan Province.

History

Usage metrics

    Expert Opinion on Drug Safety

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC